Chugai Pharmaceutical (OTCMKTS:CHGCY) & Milestone Pharmaceuticals (NASDAQ:MIST) Head-To-Head Analysis

Milestone Pharmaceuticals (NASDAQ:MIST) and Chugai Pharmaceutical (OTCMKTS:CHGCY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations.

Risk and Volatility

Milestone Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Chugai Pharmaceutical has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Milestone Pharmaceuticals and Chugai Pharmaceutical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1	1	3	1	2.67
Chugai Pharmaceutical	0	2	1	1	2.75

Milestone Pharmaceuticals presently has a consensus price target of $7.25, suggesting a potential upside of 559.09%. Given Milestone Pharmaceuticals’ higher probable upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Chugai Pharmaceutical.

Profitability

This table compares Milestone Pharmaceuticals and Chugai Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Chugai Pharmaceutical	35.09%	23.71%	19.96%

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Chugai Pharmaceutical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$2.34 million	58.45	-$63.06 million	($0.69)	-1.59
Chugai Pharmaceutical	$8.41 billion	8.43	$2.91 billion	$0.92	23.42

Chugai Pharmaceutical has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Chugai Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.0% of Chugai Pharmaceutical shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Chugai Pharmaceutical beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.